by: Sharon Klahr Coey
Novartis wants to help patients overcome the hurdles in specialized eye disease treatment with the help of a new digital tool.
The Swiss drugmaker worked with disease management app company smartpatient to create an adherence and education module inside the MyTherapy app specifically for wet age-related macular degeneration (AMD) patients. Called “See What’s Next,” the new feature includes information and resources to help patients better understand and manage their condition.
Novartis initially reached out to smartpatient when it noticed a pattern of patients who would come in for one or two injections of its anti-vascular endothelial growth factor therapy treatment Beovu, but did not return.
Read more: https://www.fiercepharma.com/marketing/novartis-joins-mytherapy-app-to-help-manage-wet-macular-degeneration